A PYMNTS Company

US/UK: Pfizer still has a chance to ink industry’s largest takeover

By  |  August 6, 2014

US-based pharmaceutical giant Pfizer could still ink the industry’s largest takeover even after being rejected for such a deal by UK’s AstraZeneca, say reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    AstraZeneca rejected Pfizer’s takeover offer last May, a deal that would have been a record purchase for the market at $118 billion. But Pfizer may now pursue AstraZeneca rival GlaxoSmithKline, also based in the UK, and also for $118 billion.

    No deal has been inked, and reports say that Pfizer could even target Ireland-based Actavis for a $57 billion acquisition. Both would strategically expand Pfizer’s drug portfolio.

    According to reports, Pfizer is looking to acquire a major pharmaceutical company abroad as it looks to relocate its headquarters and take advantage of lower tax rates overseas.

    Full content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.